osimertinib
astrazeneca
['elios']
 presenting analyses from elios. paired biopsies only feasible in 39%. met in 17%. no data on survival based on molecular alterations, but interesting genomic and proteomic analyses #esmo22 
Medical Oncologist, Translational Researcher, Peter Mac. Tweets are my own opinions. Musician (@mayhemtomi) https://t.co/f3ccD2Ml7v